1.Experimental study on inhibition of restenosis by osteopontin oligopeptide antagonist after de-endothelium.
Jie LU ; Mei HAN ; Jin-kun WEN ; Jing-jing LI
Chinese Journal of Applied Physiology 2007;23(4):495-499
AIMOsteopontin 13-peptide(Gly158-Lys170), containing multi-function domains was used to inhibit the VSMC adhesion, migration. The mechanism of 13-peptide inhibiting neointima formation was investigated.
METHODSThe effect of 13-peptide on VSMC adhesion was tested by adhesion assay. The restenosis model was prepared balloon injury after administration of 13-peptide for 1 h, and then the 13-peptide was given by an intravenous drip for 7 days. The expression changes of OPN, FAK, ILK in vessel wall were detected by immunohistochemistry and Western blot.
RESULTSThe 13-peptide dose-dependently reduced adhesion of VSMC in OPN matrix, and the infiltration of macrophage in vessel wall also was reduced in the treatment group after balloon injury. The expression of OPN, FAK, ILK was down-regulated following with the inhibition of neointima thickening.
CONCLUSIONThe OPN 13-peptide can inhibit inflammation and neointima formation by blocking the binding of OPN to it's receptors.
Animals ; Cell Adhesion ; drug effects ; Cells, Cultured ; Disease Models, Animal ; Male ; Muscle, Smooth, Vascular ; cytology ; drug effects ; metabolism ; Osteopontin ; pharmacology ; Rats ; Rats, Sprague-Dawley ; Tunica Intima ; pathology
2.In vivo distribution of c-myc antisense oligodeoxynucleotides local delivered by gelatin-coated platinum-iridium stents in rabbits and its effect on apoptosis.
Xin-xia ZHANG ; Chang-cong CUI ; Xiang-guang XU ; Xue-song HU ; Wei-hua FANG ; Bi-juan KUANG
Chinese Medical Journal 2004;117(2):258-263
BACKGROUNDPost-stenting restenosis is a significant clinical problem, involving vascular smooth muscle cells (VSMCs) proliferation and apoptosis. It is reported that c-myc antisense oligodeoxynucleotides (ASODNs) local delivered by catheter can inhibit VSMCs proliferation. This study was designed to assess tissue distribution of c-myc ASODN local delivered using gelatin-coated platinum-iridium (Pt-Ir) stents, and its effect on apoptosis of VSMCs.
METHODSGelatin-coated Pt-Ir stents that had absorbed caroboxyfluorescein-5-succimidyl ester (FAM) labeled c-myc ASODNs (550 microg per stent) were implanted into the right carotid arteries of 6 rabbits. Tissue samples were obtained at 45 minutes, 2 hours, and 6 hours. Tissue distribution of c-myc ASODNs was assessed by fluorescence microscopy. In addition, 32 rabbits were randomly divided into two groups. Rabbits in the control group (n = 16) were implanted with gelatin-coated Pt-Ir stents, and those in the treatment group (n = 16) were implanted with gelatin-coated stents that had absorbed c-myc ASODNs. 7, 14, 30, or 90 days (n = 4, respectively, for each group) after the stenting procedure, the stented segments were harvested, and histopathological examinations were performed to calculate neointimal area and mean neointimal thickness. The expression of c-myc was assessed using in situ hybridization (ISH) and immunohistochemical methods. Apoptotic VSMCs were detected using terminal deoxynucleotidyl transferase mediated dUTP nick end labeling (TUNEL) and transmission electron microscope (TEM).
RESULTSAccording to fluorescence microscopic results, FAM-labeled c-myc ASODNs were concentrated in the target vessel media at the 45 minutes time point, and then dispersed to the adventitia. Morphometric analysis showed that neointimal area and mean neointimal thickness increased continuously up to 90 days after stent implantation, but that total neointimal area and mean neointimal thickness were less in the treatment group than in the control group at all time points (P < 0.0001). At day 7 and day 14 after stenting, there were no detectable apoptotic cells in either group. However, apoptotic cells were present in the neointima 30 and 90 days after stenting, and the number of apoptotic cells was less at 30 days than at 90 days. Meanwhile, c-myc ASODNs appeared to induce apoptosis in more cells in the treatment group than that in the control group. Typical apoptotic VSMCs were observable under TEM. The expression of c-myc was positive in the control group and negative or weakly positive in the c-myc ASODN treatment group, according to both ISH and immunohistochemical examination.
CONCLUSIONGelatin-coated Pt-Ir stent mediated local delivery of c-myc ASODNs is feasible. The localization of c-myc ASODN is primarily in the target vessel walls. c-myc ASODNs can inhibit VSMCs proliferation and induce its apoptosis after local delivery in vivo.
Animals ; Apoptosis ; drug effects ; Carotid Arteries ; Female ; Gelatin ; Genes, myb ; genetics ; In Situ Hybridization ; Iridium ; Male ; Microscopy, Fluorescence ; Myocytes, Smooth Muscle ; pathology ; Oligodeoxyribonucleotides, Antisense ; administration & dosage ; metabolism ; pharmacology ; Platinum ; Rabbits ; Random Allocation ; Stents ; Tissue Distribution ; Tunica Intima ; metabolism ; Tunica Media ; metabolism
3.Effects of rapamycin on Rho-kinase and p27 mRNA expressions in a porcine coronary intimal proliferation model induced by interleukin-1beta.
Zhi-lin MIAO ; Ding-yin ZENG ; Xi-zhuo SUN ; Xu-chen ZHOU ; Ying CHENG ; Qi-gang GUAN ; Li ZHANG ; Xue-zhi HE ; Feng-tong HAN
Chinese Journal of Cardiology 2006;34(5):445-449
OBJECTIVETo observe the effects of rapamycin on the expressions of Rho-kinase and p27 mRNA during vascular intimal proliferation in a porcine model of coronary stenosis induced by interleukin-1beta (IL-1beta).
METHODSThe proximal segments of LAD and LCX were wrapped with cotton mesh that had absorbed sepharose bead solution with or without IL-1beta. Selective coronary angiography was performed two weeks later and the animals were killed for collecting the samples for histopathology and RT-PCR analyzing of Rho-kinase and p27 mRNA.
RESULTSThe expressions of Rho-kinase and p27 mRNA could be visualized in normal coronary wall. The expression of Rho-kinase mRNA was significantly enhanced and the expression of p27 mRNA was significantly decreased during the process of intimal proliferation induced by IL-1beta. Rapamycin significantly inhibited the intimal proliferation, reduced the infiltration of inflammatory cells, reduced the expression of Rho-kinase mRNA and increased the expression of p27 mRNA.
CONCLUSIONSThe expression of Rho-kinase mRNA is upregulated and p27 mRNA downregulated in coronary artery stenosis induced by IL-1beta and these effects could be abolished by cotreatment with rapamycin.
Animals ; Coronary Angiography ; Coronary Vessels ; drug effects ; metabolism ; pathology ; Disease Models, Animal ; Interleukin-1beta ; pharmacology ; Male ; RNA, Messenger ; metabolism ; Sirolimus ; pharmacology ; Swine ; Tunica Intima ; drug effects ; metabolism ; pathology ; rho-Associated Kinases ; metabolism
4.Emodin prevents intima thickness via Wnt4/Dvl-1/beta-catenin signaling pathway mediated by miR-126 in balloon-injured carotid artery rats.
Jun Yi HUA ; Yu Zhou HE ; Yun XU ; Xu Hong JIANG ; Wu YE ; Zhi Min PAN
Experimental & Molecular Medicine 2015;47(6):e170-
Neointimal proliferation after vascular injury is a key mechanism of restenosis, a major cause of percutaneous transluminal angioplasty failure and artery bypass occlusion. Emodin, an anthraquinone with multiple physiological activities, has been reported to inhibit proliferation of vascular smooth muscle cells (VSMCs) that might cause intimal arterial thickening. Thus, in this study, we established a rat model of balloon-injured carotid artery and investigated the therapeutic effect of emodin and its underlying mechanism. Intimal thickness was analyzed by hematoxylin and eosin staining. Expression of Wnt4, dvl-1, beta-catenin and collagen was determined by immunohistochemistry and/or western blotting. The proliferation of VSMC was evaluated by MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay and electron microscopy. MicroRNA levels were quantified by real-time quantitative PCR. Emodin relieved injury-induced artery intimal thickness. Results of western blots and immunohistochemistry showed that emodin suppressed expression of signaling molecules Wnt4/Dvl-1/beta-catenin as well as collagen protein in the injured artery. In addition, emodin enhanced expression of an artery injury-related microRNA, miR-126. In vitro, MTT assay showed that emodin suppressed angiotensin II (AngII)-induced proliferation of VSMCs. Emodin reversed AngII-induced activation of Wnt4/Dvl-1/beta-catenin signaling by increasing expression of miR-126 that was strongly supported by transfection of mimic or inhibitor for miR-126. Emodin prevents intimal thickening via Wnt4/Dvl-1/beta-catenin signaling pathway mediated by miR-126 in balloon-injured carotid artery of rats.
Adaptor Proteins, Signal Transducing/*metabolism
;
Animals
;
Carotid Arteries/drug effects/metabolism/pathology
;
Carotid Artery Injuries/*drug therapy/metabolism/pathology
;
Cell Proliferation/drug effects
;
Emodin/*therapeutic use
;
Male
;
MicroRNAs/*metabolism
;
Phosphoproteins/*metabolism
;
Rats
;
Rats, Sprague-Dawley
;
Signal Transduction/drug effects
;
Tunica Intima/*drug effects/metabolism/pathology
;
Wnt4 Protein/*metabolism
;
beta Catenin/*metabolism
5.Effect of Panax notoginseng saponins on vascular intima hyperplasia and PCNA expression in rat aorta after balloon angioplasty.
Jianling WANG ; Lu WU ; Wei ZHANG ; Changqing DENG
China Journal of Chinese Materia Medica 2009;34(6):735-739
OBJECTIVETo explore the effect and the mechanism of panax notoginseng saponins (PNS) on the vascular intima hyperplasia and expression of proliferating cell nuclear antigen (PCNA) after aortic intima injury induced ballcon in rats.
METHODModel of aortic intima denudation in rats was established by 2.0 forgarty. The rats were randomly divided into sham group, model group, PNS group and atorvastatin group. Drugs were administered at the second day after the aortic intima injury for 14 days. The injured thoracic aorta segment were taken to detected the vascular morphological changes and expression of PCNA by histomorphology and immunohistochemic methods.
RESULTThe intimal area (IA), intimal thickness (IT), hyperplasia ratio of intimal area (HRIA), the ratio of intimal/mesolamella area and thickness in the model group were significantly higher than those of the sham operation (P<0.01). The above indexes in PNS and atorvastatin group were markedly lower than those in the model group (P<0.05). Compared with the sham group, the expression of PCNA in the model was enhanced remarkably (P<0.01). Compared with the model group, the expression of PCNA in PNS and atorvastatin group was significantly lowered (P<0.01).
CONCLUSIONPNS could inhibit intima hyperplasia by inhibiting proliferation of the vascular smooth muscle cell after vascular intima injury.
Angioplasty, Balloon, Coronary ; Animals ; Aorta ; drug effects ; metabolism ; pathology ; Cell Proliferation ; drug effects ; Gene Expression Regulation ; drug effects ; Hyperplasia ; drug therapy ; metabolism ; pathology ; therapy ; Male ; Panax notoginseng ; chemistry ; Proliferating Cell Nuclear Antigen ; metabolism ; Rats ; Saponins ; administration & dosage ; pharmacology ; therapeutic use ; Tunica Intima ; drug effects ; metabolism ; pathology
6.Rutaecarpine Inhibits Intimal Hyperplasia in A Balloon-Injured Rat Artery Model.
Yang XU ; Xiu-Ping CHEN ; Feng ZHANG ; Hua-Hua HOU ; Jing-Yi ZHANG ; Shu-Xian LIN ; An-Sheng SUN
Chinese journal of integrative medicine 2018;24(6):429-435
OBJECTIVETo investigate the effect and potential mechanisms of rutaecarpine (Rut) in a rat artery balloon-injury model.
METHODSThe intimal hyperplasia model was established by rubbing the endothelia with a balloon catheter in the common carotid artery (CCA) of rats. Fifty rats were randomly divided into five groups, ie. sham, model, Rut (25, 50 and 75 mg/kg) with 10 rats of each group. The rats were treated with or without Rut (25, 50, 75 mg/kg) by intragastric administration for 14 consecutive days following injury. The morphological changes of the intima were evaluated by hematoxylin-eosin staining. The expressions of proliferating cell nuclear antigen (PCNA) and smooth muscle (SM) α-actin in the ateries were assayed by immunohistochemical staining. The mRNA expressions of c-myc, extracellular signal-regulated kinase 2 (ERK2), MAPK phosphatase-1 (MKP-1) and endothelial nitric oxide synthase (eNOS) were determined by real-time reverse transcription-polymerase chain reaction. The protein expressions of MKP-1 and phosphorylated ERK2 (p-ERK2) were examined by Western blotting. The plasma contents of nitric oxide (NO) and cyclic guanosine 3',5'-monophosphate (cGMP) were also determined.
RESULTSCompared with the model group, Rut treatment significantly decreased intimal thickening and ameliorated endothelial injury (P<0.05 or P<0.01). The positive expression rate of PCNA was decreased, while the expression rate of SM α-actin obviously increased in the vascular wall after Rut (50 and 75 mg/kg) administration (P<0.05 or P<0.01). Furthermore, the mRNA expressions of c-myc, ERK2 and PCNA were downregulated while the expressions of eNOS and MKP-1 were upregulated (P<0.05 or P<0.01). The protein expressions of MKP-1 and the phosphorylation of ERK2 were upregulated and downregulated after Rut (50 and 75 mg/kg) administration (P<0.05 or P<0.01), respectively. In addition, Rut dramatically reversed balloon injury-induced decrease of NO and cGMP in the plasma (P<0.05 or P<0.01).
CONCLUSIONRut could inhibit the balloon injury-induced carotid intimal hyperplasia in rats, possibly mediated by promotion of NO production and inhibiting ERK2 signal transduction pathways.
Actins ; metabolism ; Animals ; Carotid Arteries ; drug effects ; metabolism ; pathology ; Carotid Artery Injuries ; drug therapy ; genetics ; pathology ; Cyclic GMP ; blood ; Disease Models, Animal ; Gene Expression Regulation ; drug effects ; Hyperplasia ; Indole Alkaloids ; pharmacology ; therapeutic use ; Male ; Nitric Oxide ; blood ; Phosphorylation ; drug effects ; Proliferating Cell Nuclear Antigen ; metabolism ; Quinazolines ; pharmacology ; therapeutic use ; RNA, Messenger ; genetics ; metabolism ; Rats, Sprague-Dawley ; Tunica Intima ; drug effects ; pathology
7.Effect of compound Danshen dripping pills combined with atorvastatin on restenosis after angioplasty in rabbits.
Jieli SONG ; Jinpei ZENG ; Yongxia ZHANG ; Pengfei LI ; Lihong ZHANG ; Cibin CHEN
Journal of Southern Medical University 2014;34(9):1337-1341
OBJECTIVETo study the effect of compound Danshen dripping pills and atorvastatin on restenosis after abdominal aorta angioplasty in rabbits.
METHODSRabbit models of abdominal aorta restenosis after angioplasty were established and treated with saline (group A), compound Danshen dripping pills (group B), atorvastatin (group C), or compound Danshen dripping pills plus atorvastatin (group D). HE staining was used to determine the thickness of arterial intimal hyperplasia and assess the morphological changes of the narrowed artery. Immunohistochemistry was employed to detect the expression of nuclear factor-κB (NF-κB) and monocyte chemoattractant protein-1 (MCP-1).
RESULTSCompared with group A, the 3 treatment groups showed significant increased vascular cavity area and reduced intimal area and percentage of intimal hyperplasia (P<0.05). The vascular cavity area, intimal area and percentage of intimal hyperplasia levels differed significantly between group D and groups B and C (P<0.05). Immunohistochemistry showed a significant reduction of the expression rate of NF-κB and MCP-1 in the 3 treatment groups compared with group A (P<0.05), and the reduction was especially obvious in group D (P<0.05).
CONCLUTIONSCompound danshen dripping pills combined with atorvastatin produces better effects than the drugs used alone in inhibiting vascular smooth muscle cell proliferation in rabbits after abdominal aorta angioplasty possibly due to a decreased expression of MCP-1 as a result of NF-κB inhibition.
Angioplasty ; Animals ; Aorta ; pathology ; Atorvastatin Calcium ; Cell Proliferation ; Chemokine CCL2 ; metabolism ; Drugs, Chinese Herbal ; pharmacology ; Heptanoic Acids ; pharmacology ; Hyperplasia ; Myocytes, Smooth Muscle ; drug effects ; NF-kappa B ; metabolism ; Phenanthrolines ; Pyrroles ; pharmacology ; Rabbits ; Salvia miltiorrhiza ; chemistry ; Tunica Intima
8.Effects of control-releasing arsenic trioxide-eluting stent on intimal smooth muscle cells and type III collagen in canine coronary artery post-stent model.
Jun-Li ZHAO ; Bao-Gui SUN ; Qin-Zhu WEN
Chinese Journal of Integrated Traditional and Western Medicine 2010;30(6):636-639
OBJECTIVETo study the safety and efficacy of control-releasing arsenic trioxide (As2O3)-eluting stent on intimal smooth muscle cells (SMC) and type III collagen (CIII) in canine coronary artery post-stent model.
METHODSTwenty-four experimental canines were equally divided into 4 groups, the three tested groups were deployed by stents with different dosage of As2O3 (1.6 microg/mm2, 2.4 microg/mm2 and 3.2 microg/mm2 in low, median and high dose groups, respectively) and coated with polybutyl methacrylate/nano silica and poly-lactide-coglycolide in mild oversizing (stent/vessel ratio of 1.3:1) in left anterior descending (LAD) or circumflex coronary arteries (LCX), while the control group only by simple coated stent without As2O3. The effect was assessed 4 weeks after stent implantation in terms of vascular histomorphology, and changes of SMC and C III expressions were detected using immunohistochemical analysis.
RESULTSSubintimal hemorrhage, medial/adventitial necrosis, thrombosis and inflammatory cell infiltration were not found and integral endothelium could be seen under screening electron microscopy in all groups. Positive expression of SMC and CIII in the tested groups, especial in the high dose As2O3 group, was more weaker than that in control group. Histo-morphological analysis showed that the neo-genetic intimal area and vascular stenosis were lower, but the mean luminal diameter was larger in the three tested groups than that in the control group (P < 0.01). Comparisons of various indices between tested groups treated by different doses of As2O3 showed that the difference between high/median dose vs. low dose was significant (P < 0.01), but that between high dose vs. median dose was insignificant (P > 0.05).
CONCLUSIONControl-releasing As2O3-eluting stent shows a reliable and safe effect in preventing and treating post-stent restenosis by its dose-dependent inhibition on expressions of SMC and CIII to suppress the neo-genesis of intimal hyperplasia.
Animals ; Arsenicals ; administration & dosage ; pharmacology ; Collagen Type III ; metabolism ; Coronary Restenosis ; etiology ; prevention & control ; Coronary Vessels ; metabolism ; pathology ; Dogs ; Drug-Eluting Stents ; Female ; Implants, Experimental ; Male ; Muscle, Smooth, Vascular ; drug effects ; metabolism ; pathology ; Oxides ; administration & dosage ; pharmacology ; Tunica Intima ; drug effects ; pathology
9.Triptolide-eluting stent prevents porcine coronary artery in-stent restenosis by affecting PCNA and P27(kip1) expression.
Dong-feng LU ; Jing HUANG ; Hao WU ; Xiao YUAN ; Li ZHANG
Journal of Southern Medical University 2007;27(5):667-670
OBJECTIVETo investigate the effectiveness and safety of triptolide-eluting stents implanted in porcine coronary arteries for restenosis prevention, and its effect on the expression of proliferating cell nuclear antigen (PCNA) and P27(kip1).
METHODSTen triptolide-eluting stents and 10 stainless steel stents (control) were implanted in 20 porcine coronary arteries at random. Four weeks later, angiography of the arteries was performed along with also histopathological and immunochemical examinations.
RESULTSThe in-stent minimal lumen diameter of triptolide group was significantly greater, and the neointimal area significantly smaller, than those of the control group (P<0.05). PCNA expression was significantly lower while P27(kip1) protein significantly higher in triptolide group than in the control group (P<0.05).
CONCLUSIONTriptolide-eluting stent can effectively inhibit neointimal formation to prevent restenosis in porcine coronary artery 4 weeks after implantation, probably by inhibiting P27(kip1) expression and consequently vascular smooth muscle cell proliferation.
Animals ; Anti-Inflammatory Agents, Non-Steroidal ; therapeutic use ; Coronary Restenosis ; prevention & control ; Coronary Vessels ; drug effects ; metabolism ; pathology ; Cyclin-Dependent Kinase Inhibitor p27 ; biosynthesis ; Diterpenes ; therapeutic use ; Drug-Eluting Stents ; Epoxy Compounds ; therapeutic use ; Immunohistochemistry ; Male ; Phenanthrenes ; therapeutic use ; Proliferating Cell Nuclear Antigen ; biosynthesis ; Random Allocation ; Swine ; Time Factors ; Tunica Intima ; drug effects ; metabolism ; pathology
10.PPARgamma modulates vascular smooth muscle cell phenotype via a protein kinase G-dependent pathway and reduces neointimal hyperplasia after vascular injury.
Han Mo YANG ; Baek Kyung KIM ; Ju Young KIM ; Yoo Wook KWON ; Sooryeonhwa JIN ; Joo Eun LEE ; Hyun Jai CHO ; Hae Young LEE ; Hyun Jae KANG ; Byung Hee OH ; Young Bae PARK ; Hyo Soo KIM
Experimental & Molecular Medicine 2013;45(11):e65-
Vascular smooth muscle cells (VSMCs) undergo phenotypic changes in response to vascular injury such as angioplasty. Protein kinase G (PKG) has an important role in the process of VSMC phenotype switching. In this study, we examined whether rosiglitazone, a peroxisome proliferator-activated receptor (PPAR)-gamma agonist, could modulate VSMC phenotype through the PKG pathway to reduce neointimal hyperplasia after angioplasty. In vitro experiments showed that rosiglitazone inhibited the phenotype change of VSMCs from a contractile to a synthetic form. The platelet-derived growth factor (PDGF)-induced reduction of PKG level was reversed by rosiglitazone treatment, resulting in increased PKG activity. This increased activity of PKG resulted in phosphorylation of vasodilator-stimulated phosphoprotein at serine 239, leading to inhibited proliferation of VSMCs. Interestingly, rosiglitazone did not change the level of nitric oxide (NO) or cyclic guanosine monophosphate (cGMP), which are upstream of PKG, suggesting that rosiglitazone influences PKG itself. Chromatin immunoprecipitation assays for the PKG promoter showed that the activation of PKG by rosiglitazone was mediated by the increased binding of Sp1 on the promoter region of PKG. In vivo experiments showed that rosiglitazone significantly inhibited neointimal formation after balloon injury. Immunohistochemistry staining for calponin and thrombospondin showed that this effect of rosiglitazone was mediated by modulating VSMC phenotype. Our findings demonstrate that rosiglitazone is a potent modulator of VSMC phenotype, which is regulated by PKG. This activation of PKG by rosiglitazone results in reduced neointimal hyperplasia after angioplasty. These results provide important mechanistic insight into the cardiovascular-protective effect of PPARgamma.
Animals
;
Aorta/injuries/metabolism/*pathology
;
Calcium-Binding Proteins/genetics/metabolism
;
Cell Proliferation
;
Cyclic GMP/metabolism
;
Cyclic GMP-Dependent Protein Kinases/genetics/*metabolism
;
Hyperplasia/metabolism
;
Microfilament Proteins/genetics/metabolism
;
Muscle, Smooth, Vascular/metabolism/pathology
;
Myocytes, Smooth Muscle/drug effects/*metabolism
;
Nitric Oxide/metabolism
;
PPAR gamma/agonists/*metabolism
;
Promoter Regions, Genetic
;
Rats
;
Rats, Sprague-Dawley
;
Sp1 Transcription Factor/metabolism
;
Thiazolidinediones/pharmacology
;
Thrombospondins/genetics/metabolism
;
Tunica Intima/metabolism/*pathology
;
Vascular System Injuries/*metabolism/pathology